Clinical trials
catalyst calendar across sponsors →Studies where AVLN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 6 tracked-famous managers (CITADEL ADVISORS LLC, Balyasny Asset Management L.P., D. E. Shaw & Co., Inc., Hudson Bay Capital Management LP, SOROS FUND MANAGEMENT LLC, +1 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)NCT06951217To evaluate the long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications (AP01).Open-label · Treatment | Phase 2 | Recruiting | Combination product: AP01 | Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 340 | 2031-12-31 | in 1,960 d | 2026-08-07 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: AP01 · Other: Placebo | Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis | 375 | Jun 2027 | ≤ 315 d | 2026-07-02 |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382Change from baseline in the morning pre-dose forced vital capacity at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: AP02, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 160 | Dec 2026 | ≤ 134 d | 2026-08-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19